Last reviewed · How we verify

ChimeriVax-JE, Japanese Encephalitis vaccine

Sanofi · Phase 3 active Biologic

ChimeriVax-JE, Japanese Encephalitis vaccine is a Live attenuated chimeric vaccine Biologic drug developed by Sanofi. It is currently in Phase 3 development for Japanese encephalitis prevention in endemic and at-risk populations. Also known as: ChimeriVax™.

ChimeriVax-JE is a live attenuated chimeric vaccine that uses a yellow fever virus backbone expressing Japanese encephalitis virus envelope proteins to induce protective immunity against Japanese encephalitis.

ChimeriVax-JE is a live attenuated chimeric vaccine that uses a yellow fever virus backbone expressing Japanese encephalitis virus envelope proteins to induce protective immunity against Japanese encephalitis. Used for Japanese encephalitis prevention in endemic and at-risk populations.

At a glance

Generic nameChimeriVax-JE, Japanese Encephalitis vaccine
Also known asChimeriVax™
SponsorSanofi
Drug classLive attenuated chimeric vaccine
ModalityBiologic
Therapeutic areaInfectious Disease / Immunology
PhasePhase 3

Mechanism of action

The vaccine combines the attenuated yellow fever 17D vaccine strain with genes encoding the prM and E surface proteins of Japanese encephalitis virus. This chimeric approach leverages the well-established safety and immunogenicity of the YF 17D backbone while presenting JE-specific antigens to elicit both humoral and cellular immune responses against Japanese encephalitis virus.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ChimeriVax-JE, Japanese Encephalitis vaccine

What is ChimeriVax-JE, Japanese Encephalitis vaccine?

ChimeriVax-JE, Japanese Encephalitis vaccine is a Live attenuated chimeric vaccine drug developed by Sanofi, indicated for Japanese encephalitis prevention in endemic and at-risk populations.

How does ChimeriVax-JE, Japanese Encephalitis vaccine work?

ChimeriVax-JE is a live attenuated chimeric vaccine that uses a yellow fever virus backbone expressing Japanese encephalitis virus envelope proteins to induce protective immunity against Japanese encephalitis.

What is ChimeriVax-JE, Japanese Encephalitis vaccine used for?

ChimeriVax-JE, Japanese Encephalitis vaccine is indicated for Japanese encephalitis prevention in endemic and at-risk populations.

Who makes ChimeriVax-JE, Japanese Encephalitis vaccine?

ChimeriVax-JE, Japanese Encephalitis vaccine is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is ChimeriVax-JE, Japanese Encephalitis vaccine also known as anything else?

ChimeriVax-JE, Japanese Encephalitis vaccine is also known as ChimeriVax™.

What drug class is ChimeriVax-JE, Japanese Encephalitis vaccine in?

ChimeriVax-JE, Japanese Encephalitis vaccine belongs to the Live attenuated chimeric vaccine class. See all Live attenuated chimeric vaccine drugs at /class/live-attenuated-chimeric-vaccine.

What development phase is ChimeriVax-JE, Japanese Encephalitis vaccine in?

ChimeriVax-JE, Japanese Encephalitis vaccine is in Phase 3.

What are the side effects of ChimeriVax-JE, Japanese Encephalitis vaccine?

Common side effects of ChimeriVax-JE, Japanese Encephalitis vaccine include Injection site reactions (pain, erythema, swelling), Fever, Headache, Myalgia, Fatigue.

Related